Emerging studies have shown that signaling pathways such as HER2,163 HER3, ALK1, MEK, RAF, CDK, IDO1, CCR4, and Nectin 4 can also be used as targets for HNSCC clinical trials. This evidence concerns the gene MAP2K7 and head and neck squamous cell carcinoma.